174822-86-7

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(2-hydroxyphenyl)-, 1,1-dimethylethyl ester
• Synonyms: 1-(tert-butyloxycarbonyl)-4-(2-hydroxyphenyl)piperidine;1-Boc-4-(2-hydroxy-phenyl)-piperidine;4-(2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 174822-86-7
• Molecular Formula: C16H23NO3
• Molecular Weight: 277.364
• Mol File: 174822-86-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(2-hydroxyphenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(2-hydroxyphenyl)-, 1,1-dimethylethyl ester(174822-86-7)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(2-hydroxyphenyl)-, 1,1-dimethylethyl ester(174822-86-7)

Safety Data

• Hazardous Substances Data: 174822-86-7(Hazardous Substances Data)

Usage

Molecular structure

The compound has a complex molecular structure that consists of a piperidine ring attached to a carboxylic acid group and a 2-hydroxyphenyl group with a t-butyl ester.

Ester derivative

It is an ester derivative of 1-piperidinecarboxylic acid and 4-(2-hydroxyphenyl), indicating that it is formed by the reaction of the carboxylic acid group with an alcohol (in this case, the 2-hydroxyphenol group).

Biological activity

The compound has potential biological activities due to its structural features, which may make it useful in the pharmaceutical industry.

Ongoing research

Research and analysis of the properties and potential uses of this compound are ongoing, indicating that its full range of applications and effects are not yet fully understood.

Upstream product

• 1378810-75-3 C₁₁H₁₄NO^(1-)*Na⁽¹⁺⁾ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161609-76-3 4-(2-hydroxyphenyl)-piperidine 
• 58333-75-8 4-(2-methoxyphenyl)piperidine 
• 1269025-34-4 4-(2-hydroxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 910605-43-5 4-(2-hydroxyphenyl)piperidine hydrobromide 
• 1048970-17-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1201927-69-6 C₁₈H₂₀FNO 
• 899356-74-2 C₁₇H₁₉NO 
• 1201927-87-8 C₁₇H₁₈ClNO 
• 1201927-81-2 C₁₇H₁₈FNO 
• 1201927-84-5 C₁₇H₁₈FNO 
• 1201927-92-5 C₁₈H₂₀FNO 
• 1201927-68-5 C₁₈H₂₁NO 
• 1201927-75-4 C₁₈H₂₀FNO 
• 951774-81-5 C₂₁H₂₉N₃O₃ 
• 951774-78-0 C₁₈H₂₆BrNO₃ 
• 947614-65-5 C₂₂H₃₄N₂O₃ 
• 910605-44-6 4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 910605-27-5 4-[2-(2-chloro-ethoxy)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 174822-96-9 4-(2-trifluoromethylsulfonyloxyphenyl)piperidine 

Relevant articles and documents

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Enantiospecific sp2–sp3 Coupling of ortho- and para-Phenols with Secondary and Tertiary Boronic Esters

The coupling of ortho- and para-phenols with secondary and tertiary boronic esters has been explored. In the case of para-substituted phenols, after reaction of a dilithio phenolate species with a boronic ester, treatment with Ph3BiF2 or Martin's sulfurane gave the coupled product with complete enantiospecificity. The methodology was applied to the synthesis of the broad spectrum antibacterial natural product (?)-4-(1,5-dimethylhex-4-enyl)-2-methyl phenol. For ortho-substituted phenols, initial incorporation of a benzotriazole on the phenol oxygen atom was required. Subsequent ortho-lithiation and borylation gave the coupled product, again with complete stereospecificity.

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.